The Japan Next-Generation Sequencing (NGS) based RNA-sequencing market utilizes advanced technology to rapidly and comprehensively analyze all the RNA molecules present in a biological sample. This is essential for understanding gene activity and regulation in Japanese research and clinical settings, particularly for advancing personalized medicine, developing new drug targets, and gaining deeper insights into complex diseases like cancer by examining genetic expression patterns.
The NGS-based RNA-sequencing Market in Japan is anticipated to grow steadily at a CAGR of XX% from 2025 to 2030, rising from an estimated US$ XX billion in 2024–2025 to US$ XX billion by 2030.
The global NGS-based RNA-sequencing market was valued at $2.5 billion in 2022 and is projected to reach $5.5 billion by 2027, with a Compound Annual Growth Rate (CAGR) of 17.2%.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=102977816
Drivers
The Japan NGS-based RNA-sequsequencing market is strongly driven by the nation’s proactive strategy toward precision medicine and the substantial investment directed towards genomic and transcriptomic research. The rising incidence of chronic and complex diseases, particularly various types of cancer, necessitates highly detailed molecular profiling for accurate diagnosis, prognosis, and therapeutic guidance, where RNA sequencing is paramount. RNA-sequencing offers unparalleled insight into gene expression, alternative splicing, and the presence of non-coding RNAs, which are crucial for understanding disease mechanisms at a molecular level. Furthermore, the strong emphasis on translational research, converting basic biological discoveries into clinical applications, is accelerating the adoption of these advanced sequencing techniques. Government funding initiatives and a robust, advanced healthcare infrastructure support the integration of NGS-based diagnostics into clinical practice. The technology’s ability to analyze total RNA, mRNA, and various non-coding RNAs (like microRNAs and long non-coding RNAs) provides a comprehensive view of the transcriptome, which is highly valuable for drug discovery and biomarker identification efforts by major Japanese pharmaceutical and biotechnology firms. Finally, the decreasing cost and increasing throughput of next-generation sequencing platforms are making large-scale transcriptome studies economically viable, further driving sustained market momentum in both academic and commercial sectors.
Restraints
Despite the strong drivers, the NGS-based RNA-sequencing market in Japan faces several critical restraints, primarily revolving around cost, data complexity, and standardization. The high initial capital expenditure required for acquiring and maintaining advanced NGS instruments, along with the recurring costs of specialized reagents and consumables, poses a significant financial barrier, particularly for smaller laboratories and clinics. Another major restraint is the immense complexity and volume of the genomic data generated by RNA sequencing. Analyzing and interpreting this vast data requires highly specialized bioinformatic expertise, which is currently in short supply in Japan’s clinical environment. The lack of standardized protocols for RNA sample preparation, library construction, and data analysis across different research and clinical settings hinders reproducibility and comparability of results, limiting widespread clinical adoption. Furthermore, the regulatory environment for novel NGS-based diagnostic tests, while supportive of innovation, often involves complex and time-consuming validation procedures to demonstrate clinical utility and robustness, which slows market entry. Finally, concerns regarding data privacy and security, given the sensitive nature of patient genetic information, necessitate robust and compliant data management infrastructure, which presents both a technical and compliance hurdle for healthcare institutions.
Opportunities
Significant opportunities in Japan’s NGS-based RNA-sequencing market stem from the expansion into clinical diagnostics and therapeutic development. A key opportunity lies in leveraging the technology for early cancer detection and minimal residual disease (MRD) monitoring, particularly through liquid biopsy applications that analyze cell-free RNA (cfRNA). This non-invasive approach meets the increasing demand for patient-friendly diagnostic options. The robust development in single-cell RNA sequencing (scRNA-seq) presents another massive opportunity, offering highly granular biological insights into cell heterogeneity, crucial for advancing immunology, regenerative medicine, and oncology research. Japanese researchers are uniquely positioned to capitalize on scRNA-seq, given the nation’s pioneering work in stem cell technology. Furthermore, the rise of targeted RNA sequencing panels focused on specific disease markers allows for more cost-effective and focused analysis compared to whole transcriptome sequencing, facilitating quicker adoption in routine clinical settings. Partnerships between global sequencing technology providers and domestic research institutions and hospitals can accelerate technology transfer and localize the development of bioinformatics tools optimized for the Japanese language and clinical workflow. Moreover, integrating RNA-sequencing with other ‘omics’ data (genomics, proteomics) via multi-omics approaches represents a future opportunity for holistic disease understanding and the creation of highly personalized treatment regimens.
Challenges
Several challenges must be overcome for the continued growth and clinical integration of NGS-based RNA-sequencing in Japan. Technical difficulties surrounding RNA sample stability and quality represent a constant hurdle, as RNA is highly susceptible to degradation, particularly in challenging samples like formalin-fixed, paraffin-embedded (FFPE) tissues or biofluids used in liquid biopsies. Ensuring consistent and reproducible results from low-quantity or degraded samples remains a critical technical challenge. The regulatory pathway, while becoming clearer, still demands rigorous clinical validation to prove the clinical utility and cost-effectiveness of new NGS diagnostics against existing standard-of-care methods, requiring significant time and resources. Furthermore, the bottleneck in bioinformatics—the lack of skilled professionals capable of handling the exponential growth of sequencing data and developing localized, user-friendly data analysis software—limits the seamless integration of RNA-sequencing results into hospital information systems (HIS). Educating clinicians, who are traditionally reliant on established diagnostic markers, about the clinical relevance and actionability of complex RNA-sequencing data is another crucial challenge. Finally, the necessity for robust computational infrastructure for big data storage and analysis needs sustained investment to keep pace with the increasing throughput of the sequencing platforms.
Role of AI
Artificial intelligence (AI) is transforming the Japanese NGS-based RNA-sequencing market by addressing key data interpretation and complexity challenges. AI and machine learning algorithms are indispensable for the efficient analysis of the massive and complex datasets generated by RNA sequencing, enabling rapid identification of novel biomarkers, genetic variants, and subtle gene expression patterns that are often missed by conventional statistical methods. Specifically, AI models are used to improve accuracy in disease classification (e.g., cancer subtypes) and predict patient response to specific therapies based on their transcriptome profiles, significantly advancing personalized medicine efforts. In the discovery phase, AI accelerates target identification by simulating biological systems and analyzing vast public and proprietary genomic databases. Furthermore, AI plays a crucial role in enhancing the technical workflow by automating quality control steps, such as assessing sequencing read quality and detecting sample contamination or inconsistencies. Machine learning also drives the development of sophisticated bioinformatics tools, making data interpretation more accessible to non-specialist clinicians by translating complex transcriptomic findings into actionable clinical insights, thereby helping to bridge the gap between advanced research and routine clinical practice in Japan.
Latest Trends
The Japanese NGS-based RNA-sequencing market is defined by several cutting-edge trends aimed at improving resolution and accessibility. One dominant trend is the rapid adoption of single-cell RNA sequencing (scRNA-seq), which allows researchers to profile the transcriptome of individual cells, providing unprecedented resolution into complex tissues, cellular heterogeneity, and disease progression, particularly in cancer and neurological disorders. This shift is crucial for Japan’s strong focus on regenerative medicine and stem cell research. Another significant trend is the increasing use of spatial transcriptomics, which retains the positional information of gene expression within a tissue section, providing context that bulk RNA sequencing lacks. This is rapidly gaining traction in oncology research. Furthermore, the development and commercialization of targeted RNA sequencing panels are accelerating, focusing on clinically relevant genes (e.g., immune checkpoint genes or specific cancer fusion transcripts). This offers a streamlined, cost-effective alternative to whole transcriptome sequencing for routine clinical use. There is also a strong movement toward integrating RNA sequencing with liquid biopsy technologies, using plasma or serum to detect circulating tumor RNA (ctRNA) for non-invasive monitoring. Finally, technological advancements include the emergence of long-read sequencing technologies, which improve the detection and characterization of full-length RNA isoforms and splice variants, providing a more complete picture of the transcriptome.